{
  "trial_id": "NCT01477333",
  "trial_group": "hypertension",
  "generated-by-gpt4-omni-zs": {
    "gen-response": "Age, Gender, Diagnosis of PAH subtype, Duration of Tyvaso treatment, Concurrent PAH therapies (ERAs and/or PDE-5 inhibitors), Baseline hemodynamic parameters, Baseline 6-minute walk test (6MWT) distance, Baseline Borg dyspnea score, Baseline NT-proBNP levels, Baseline WHO Functional Class, Baseline heart rate, Baseline arterial and venous oxygen saturation, Baseline cardiac output, Baseline cardiac index, Baseline pulmonary vascular resistance index, Systolic blood pressure, Diastolic blood pressure, Left ventricular ejection fraction (LVEF).",
    "evaluated-by-gpt4-omni": {
      "matched_features": [
        [
          "Age",
          "Age"
        ],
        [
          "Sex: Female",
          "Gender"
        ]
      ],
      "remaining_reference_features": [
        "Categorical",
        "Male",
        "Ethnicity (NIH/OMB)",
        "Race (NIH/OMB)",
        "Region of Enrollment"
      ],
      "remaining_candidate_features": [
        "Diagnosis of PAH subtype",
        "Duration of Tyvaso treatment",
        "Concurrent PAH therapies (ERAs and/or PDE-5 inhibitors)",
        "Baseline hemodynamic parameters",
        "Baseline 6-minute walk test (6MWT) distance",
        "Baseline Borg dyspnea score",
        "Baseline NT-proBNP levels",
        "Baseline WHO Functional Class",
        "Baseline heart rate",
        "Baseline arterial and venous oxygen saturation",
        "Baseline cardiac output",
        "Baseline cardiac index",
        "Baseline pulmonary vascular resistance index",
        "Systolic blood pressure",
        "Diastolic blood pressure",
        "Left ventricular ejection fraction (LVEF)"
      ]
    },
    "processed-gen-response": "Age, Gender, Diagnosis of PAH subtype, Duration of Tyvaso treatment, Concurrent PAH therapies (ERAs and/or PDE-5 inhibitors), Baseline hemodynamic parameters, Baseline 6-minute walk test (6MWT) distance, Baseline Borg dyspnea score, Baseline NT-proBNP levels, Baseline WHO Functional Class, Baseline heart rate, Baseline arterial and venous oxygen saturation, Baseline cardiac output, Baseline cardiac index, Baseline pulmonary vascular resistance index, Systolic blood pressure, Diastolic blood pressure, Left ventricular ejection fraction (LVEF)."
  },
  "generated-by-gpt4-omni-ts": {
    "gen-response": "Age, Continuous, Sex: Female, Male, Race/Ethnicity, Customized, Region of Enrollment, Baseline 6-minute walk distance, Baseline Borg dyspnea score, Baseline NT-proBNP levels, WHO Functional Class, Baseline hemodynamic parameters (heart rate, arterial and venous oxygen saturation, cardiac output, cardiac index, pulmonary vascular resistance index), Concomitant PAH therapies, Duration of Tyvaso use,",
    "evaluated-by-gpt4-omni": {
      "matched_features": [
        [
          "Age",
          "Age"
        ],
        [
          "Sex: Female",
          "Sex: Female"
        ],
        [
          "Male",
          "Male"
        ],
        [
          "Race (NIH/OMB)",
          "Race/Ethnicity"
        ],
        [
          "Region of Enrollment",
          "Region of Enrollment"
        ]
      ],
      "remaining_reference_features": [
        "Categorical",
        "Ethnicity (NIH/OMB)"
      ],
      "remaining_candidate_features": [
        "Baseline 6-minute walk distance",
        "Baseline Borg dyspnea score",
        "Baseline NT-proBNP levels",
        "WHO Functional Class",
        "Baseline hemodynamic parameters (heart rate, arterial and venous oxygen saturation, cardiac output, cardiac index, pulmonary vascular resistance index)",
        "Concomitant PAH therapies",
        "Duration of Tyvaso use"
      ]
    },
    "processed-gen-response": "Age, Sex: Female, Male, Race/Ethnicity, Region of Enrollment, Baseline 6-minute walk distance, Baseline Borg dyspnea score, Baseline NT-proBNP levels, WHO Functional Class, Baseline hemodynamic parameters (heart rate, arterial and venous oxygen saturation, cardiac output, cardiac index, pulmonary vascular resistance index), Concomitant PAH therapies, Duration of Tyvaso use"
  },
  "generated-by-llama3-70b-in-ts": {
    "gen-response": "Age, Continuous, Sex: Female, Male, Race/Ethnicity, Customized, Region of Enrollment, Body Mass Index, Systolic Blood Pressure, Diastolic Blood Pressure, WHO Functional Class, 6-minute walk test distance, Borg dyspnea score, N-Terminal pro-brain natriuretic peptide, Pulmonary arterial hypertension diagnosis duration, Tyvaso dose, ERA and/or PDE-5 inhibitor use.",
    "evaluated-by-gpt4-omni": {
      "matched_features": [
        [
          "Age",
          "Age"
        ],
        [
          "Sex: Female",
          "Sex: Female"
        ],
        [
          "Male",
          "Male"
        ],
        [
          "Race (NIH/OMB)",
          "Race/Ethnicity"
        ],
        [
          "Region of Enrollment",
          "Region of Enrollment"
        ]
      ],
      "remaining_reference_features": [
        "Categorical",
        "Ethnicity (NIH/OMB)"
      ],
      "remaining_candidate_features": [
        "Body Mass Index",
        "Systolic Blood Pressure",
        "Diastolic Blood Pressure",
        "WHO Functional Class",
        "6-minute walk test distance",
        "Borg dyspnea score",
        "N-Terminal pro-brain natriuretic peptide",
        "Pulmonary arterial hypertension diagnosis duration",
        "Tyvaso dose",
        "ERA and/or PDE-5 inhibitor use."
      ]
    },
    "processed-gen-response": "Age, Sex: Female, Male, Race/Ethnicity, Region of Enrollment, Body Mass Index, Systolic Blood Pressure, Diastolic Blood Pressure, WHO Functional Class, 6-minute walk test distance, Borg dyspnea score, N-Terminal pro-brain natriuretic peptide, Pulmonary arterial hypertension diagnosis duration, Tyvaso dose, ERA and/or PDE-5 inhibitor use."
  },
  "generated-by-llama3-70b-in-zs": {
    "gen-response": "Age, sex, race, ethnicity, weight, height, body mass index (BMI), PAH etiology (idiopathic, heritable, associated with collagen vascular disease, HIV infection, appetite suppressant or toxin use, or repaired congenital systemic-to-pulmonary shunts), WHO Functional Class, 6-minute walk test (6MWT) distance, Borg dyspnea score, N-Terminal pro-brain natriuretic peptide (NT-proBNP) level, systolic and diastolic blood pressure, heart rate, cardiac output, cardiac index, pulmonary vascular resistance index, arterial and venous oxygen saturation, use of other PAH specific oral therapies (endothelin receptor antagonists and/or phosphodiesterase type 5 inhibitor).",
    "evaluated-by-gpt4-omni": {
      "matched_features": [
        [
          "Age",
          "Age"
        ],
        [
          "Sex: Female",
          "sex"
        ],
        [
          "Race (NIH/OMB)",
          "race"
        ],
        [
          "Ethnicity (NIH/OMB)",
          "ethnicity"
        ]
      ],
      "remaining_reference_features": [
        "Categorical",
        "Male",
        "Region of Enrollment"
      ],
      "remaining_candidate_features": [
        "weight",
        "height",
        "body mass index (BMI)",
        "PAH etiology (idiopathic, heritable, associated with collagen vascular disease, HIV infection, appetite suppressant or toxin use, or repaired congenital systemic-to-pulmonary shunts)",
        "WHO Functional Class",
        "6-minute walk test (6MWT) distance",
        "Borg dyspnea score",
        "N-Terminal pro-brain natriuretic peptide (NT-proBNP) level",
        "systolic and diastolic blood pressure",
        "heart rate",
        "cardiac output",
        "cardiac index",
        "pulmonary vascular resistance index",
        "arterial and venous oxygen saturation",
        "use of other PAH specific oral therapies (endothelin receptor antagonists and/or phosphodiesterase type 5 inhibitor)"
      ]
    },
    "processed-gen-response": "Age, sex, race, ethnicity, weight, height, body mass index (BMI), PAH etiology (idiopathic, heritable, associated with collagen vascular disease, HIV infection, appetite suppressant or toxin use, or repaired congenital systemic-to-pulmonary shunts), WHO Functional Class, 6-minute walk test (6MWT) distance, Borg dyspnea score, N-Terminal pro-brain natriuretic peptide (NT-proBNP) level, systolic and diastolic blood pressure, heart rate, cardiac output, cardiac index, pulmonary vascular resistance index, arterial and venous oxygen saturation, use of other PAH specific oral therapies (endothelin receptor antagonists and/or phosphodiesterase type 5 inhibitor)."
  }
}